These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19746253)

  • 21. Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.
    Maruyama T; Ohe T; Kurita T; Aihara N; Shimizu W
    Eur Heart J; 1995 May; 16(5):667-73. PubMed ID: 7588899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levofloxacin-induced torsades de pointes.
    Patel PD; Afshar H; Birnbaum Y
    Tex Heart Inst J; 2010; 37(2):216-7. PubMed ID: 20401298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia.
    Tran HT; Chow MS; Kluger J
    Pacing Clin Electrophysiol; 1997 Sep; 20(9 Pt 1):2275-8. PubMed ID: 9309756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in acute myelogenous leukemia.
    Otsuka M; Kanamori H; Sasaki S; Taguchi J; Harano H; Ogawa K; Matsuzaki M; Mohri H; Okubo T; Sumita S; Ochiai H
    Intern Med; 1997 Oct; 36(10):705-8. PubMed ID: 9372331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.
    Morganroth J
    Am J Cardiol; 1993 Aug; 72(6):10B-13B. PubMed ID: 8256748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.
    Atar S; Freedberg NA; Antonelli D; Rosenfeld T
    Pacing Clin Electrophysiol; 2003 Mar; 26(3):785-6. PubMed ID: 12698686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sotalol-induced torsade de pointes tachycardia in a 15-month-old infant].
    Sasse M; Paul T; Bergmann P; Kallfelz HC
    Z Kardiol; 1995 Oct; 84(10):863-6. PubMed ID: 7502575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental models of torsades de pointes.
    Weissenburger J; Davy JM; Chézalviel F
    Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Torsade de pointes with sotalol overdose treated successfully with lidocaine.
    Assimes TL; Malcolm I
    Can J Cardiol; 1998 May; 14(5):753-6. PubMed ID: 9627533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia--evidence for a significant contribution of the "cardiac memory".
    Haverkamp W; Hördt M; Breithardt G; Borggrefe M
    Clin Cardiol; 1998 Jan; 21(1):55-8. PubMed ID: 9474467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Torsades de Pointes in Coronavirus Disease 2019 Infection.
    Lalabekyan B; Kunst G; Skelton VA
    J Cardiothorac Vasc Anesth; 2021 Mar; 35(3):954-955. PubMed ID: 32753328
    [No Abstract]   [Full Text] [Related]  

  • 33. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amiodarone-induced torsade de pointes in a patient with wolff-Parkinson-White syndrome.
    Badshah A; Mirza B; Janjua M; Nair R; Steinman RT; Cotant JF
    Hellenic J Cardiol; 2009; 50(3):224-6. PubMed ID: 19465366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
    Kurita T; Ohe T; Shimizu W; Suyama K; Aihara N; Takaki H; Kamakura S; Shimomura K
    Pacing Clin Electrophysiol; 1997 Mar; 20(3 Pt 1):695-705. PubMed ID: 9080496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
    Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
    JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Torsade de pointes and QT syndrome].
    Haverkamp W; Hördt M; Borggrefe M; Breithardt G
    Med Klin (Munich); 1995 Apr; 90(4):240-5. PubMed ID: 7776938
    [No Abstract]   [Full Text] [Related]  

  • 38. Cellular basis of drug-induced torsades de pointes.
    Roden DM
    Br J Pharmacol; 2008 Aug; 154(7):1502-7. PubMed ID: 18552874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hands-on help Torsades de pointes.
    Dulak SB
    RN; 2004 Oct; 67(10):24ac1-4. PubMed ID: 15552376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.